Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive Stage Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 16 Dec 2017
At a glance
- Drugs Trilaciclib (Primary) ; Atezolizumab; Carboplatin; Etoposide
- Indications Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors G1 Therapeutics
- 08 Nov 2017 According to a G1 Therapeutics media release, topline data from this trial are expected in the first quarter of 0218.
- 03 May 2017 Status changed from active, no longer recruiting to recruiting.
- 07 Apr 2017 Status changed from not yet recruiting to active, no longer recruiting.